Daraxonrasib: Breaking Down Pancreatic Cancer’s New Breakthrough Drug

Daraxonrasib is a drug that needs little introduction – it's the potential breakthrough in pancreatic cancer therapy that everyone’s been talking about for the past few weeks. It’s a total gamechanger in the fight against one of the deadliest, most aggressive cancers.

What are the findings from the RASolute 302 trial? What does its recent FDA approval mean for pancreatic cancer therapy? And how does it impact your patients?  HOPA members Courtney Cavalieri and Benjamin Andrick sat down to discuss everything you need to know.

Check out Courtney's article on the drug in the latest issue of HOPA News.

Find out more about Daraxonrasib in HOPA's Late-Breaking News article by Michael Arnold: https://www.hoparx.org/latest-news/late-breaking-hopa-news-rasolute-302-breakthrough-in-metastatic-pancreatic-adenocarcinoma/

Interested in contributing to a future episode? Got a topic suggestion? We'd love to hear from you. Email us at ⁠⁠communications@hoparx.org⁠